Jeffrey Alan Hawkins, who serves as President and Chief Executive Officer of Quantum-Si Inc., executed two separate stock sales in late June 2026. The transactions resulted in total proceeds of $20,996 and were structured to satisfy mandatory tax withholding requirements tied to the vesting of restricted stock units.
On June 22, 2026, Mr. Hawkins disposed of 11,310 shares of Quantum-Si Class A Common Stock. The weighted average price for this initial transaction was $0.9574 per share. The specific execution prices for this block ranged between $0.9212 and $1.005. The following day, June 23, 2026, an additional 11,311 shares were sold. This second batch achieved a weighted average price of $0.899 per share, with individual prices ranging from $0.88 to $0.9291.
These divestitures were not discretionary but were required to cover federal, state, and local tax obligations arising from the vesting event. Such sell-to-cover provisions are fixed at the time of the award grant and cannot be modified by the executive. Following these transactions, Mr. Hawkins retains direct ownership of 3,669,802 shares of Quantum-Si Class A Common Stock. He continues to lead the Branford, Connecticut-based company.
The stock price has moved lower since these transactions, currently trading at $0.83. This level represents a 59% decline over the past year. Despite the recent price weakness, analysis from InvestingPro suggests that QSI may be undervalued at current levels. The platform identifies eight additional ProTips for QSI and provides a comprehensive Pro Research Report detailing the company's financial health and market outlook.
In broader corporate developments, Quantum-Si reported first-quarter earnings for 2026 that surpassed analyst expectations. The company posted an earnings per share of -$0.10, outperforming the forecasted loss of -$0.11. Revenue also exceeded projections, coming in at $258,000 against an expected $248,000.
Strategic initiatives continue to expand alongside financial reporting. Quantum-Si announced a partnership with Cell Signaling Technology designed to enhance its Proteus single-molecule protein sequencing platform. This collaboration aims to integrate Cell Signaling Technology's capabilities to improve the precision of protein and post-translational modification analysis. The company has also expanded its roadshow activities to promote the Proteus platform, targeting key cities across the United States and Europe.
In corporate governance, shareholders reelected all ten director nominees at the annual meeting. Board members, including Jonathan M. Rothberg, Ph.D., received a majority of votes, signaling continued shareholder support for the current leadership structure.